Events and Conferences

May 11-15, 2026 – Boston, MA

May 11-15, 2026 – Boston, MA

🔬  Where Cell and Gene Therapy Moves Forward

Veristat is pleased to attend the ASGCT Annual Meeting, where leaders across cell and gene therapy come together to share progress, tackle challenges, and shape what comes next. As programs advance through early-phase development, the stakes are high. Scientific complexity, evolving regulatory expectations, and the need for clear, defensible data all converge at this stage.

Our team looks forward to connecting with sponsors and innovators to discuss how Veristat supports cell and gene therapy programs with integrated regulatory, clinical, and biostatistical expertise. The focus is simple: make development capital count and enable faster, more confident decisions as therapies move closer to patients.

April 30, 2026 | Boston

⚛️  Where Clinical Strategy Meets Execution That Holds Up Under Scrutiny 

On April 30, we will be attending the Precision Clinical Trials Summit Boston, where clinical development and operations leaders come together to address the complexities shaping modern trials. As study designs evolve and expectations for speed and precision increase, success depends on more than execution. It requires clear strategy, disciplined planning, and data that supports confident decisions at every stage.

Our team looks forward to meeting with biotech and clinical leaders to discuss how Veristat helps sponsors reduce rework, improve decision speed, and make every dollar of development capital count.

May 3–5, 2026 – Basel, Switzerland 

⚛️  Where Global Biotech Comes Together 

Veristat is pleased to attend Swiss Biotech Day 2026, one of Europe’s leading biotechnology conferences, bringing together innovators, investors, and development leaders at the heart of Switzerland’s life sciences ecosystem.

As partnerships form and programs take shape, early alignment and clear development strategy play a critical role in setting therapies up for success. And as sponsors advance through early and mid-stage development, the margin for error narrows. Progress depends on disciplined clinical planning, strong statistical foundations, and regulatory clarity that holds up under scrutiny.

Our team looks forward to connecting with biotech leaders to discuss how Veristat helps move complex programs forward while making every dollar of development capital count.

🔬 Connecting with the Global Biopharma Community

Veristat is pleased to attend BIO-Europe Spring, where biotech innovators, investors, and development leaders come together to form the partnerships that move new therapies forward. As sponsors advance programs through early and mid-stage development, success increasingly depends on disciplined planning, high-quality evidence, and regulatory clarity.

Our team looks forward to meeting with biotech leaders to discuss how Veristat helps sponsors move complex therapies forward while making every dollar of development capital count.

🔬 Connecting with the Global Clinical Data and Biostatistics Community

Veristat is pleased to attend PHUSE US Connect 2026, where leaders in biostatistics, statistical programming, data science, and regulatory standards gather to advance innovation in clinical development.

As clinical programs grow more complex and regulatory expectations around data quality continue to evolve, sponsors need statistical leadership and data strategies that transform study data into clear, submission-ready evidence. Events like PHUSE bring together the experts shaping how data standards, analytics, and statistical thinking support better regulatory outcomes.

Our team looks forward to connecting with fellow data and statistical professionals and discussing how strong evidence strategies can support efficient clinical development.

Meet Veristat at BIOCHINA & CMAC: Advancing Global Clinical Development

🔬 Connecting with the Global Biotech Community

We are pleased to be attending BIOCHINA, where innovators from across the biotech ecosystem come together to discuss the future of drug development and global regulatory strategy. As more companies pursue international pathways for approval, thoughtful clinical planning and strong data strategies have never been more important. Our team looks forward to engaging with fellow leaders, sharing perspectives, and exploring how we can help advance complex therapies from development to regulatory success.

We are also looking forward to attending the CMAC Annual Meeting and spending time with colleagues across the clinical development ecosystem. It’s so valuable to step away from day-to-day program work and have thoughtful conversations about the evolving challenges in trial design, data strategy, and regulatory expectations. So we’re excited to exchange ideas, share perspectives from complex development programs, and connect with teams advancing the next generation of therapies.

Meet Veristat at SCOPE: Powering the Future of Clinical Research February 2-5, 2026

🔬 Advancing Clinical Research with Strategic Partnership

Veristat is proud to be attending SCOPE 2026, where industry leaders gather to shape the future of clinical trials, data strategy, and operational excellence. As the clinical development landscape evolves and expectations rise, our team is ready to forge new collaborations and share insights that accelerate progress and improve outcomes.

Meet Veristat at ASH Meeting and Exposition December 6-9, 2025

Veristat is excited to attend the ASH Annual Meeting and Exposition, the world’s premier event for cutting-edge research in malignant and non-malignant hematology. This year’s meeting will take place December 6–9, 2025, bringing together global experts to share groundbreaking research and clinical advances in blood disorder research, diagnosis, and treatment.

Meet Veristat at 2nd Annual Clinical Outsourcing Group CRO Summit December 2-3, 2025

Veristat is proud to participate in the 2nd Annual Clinical Outsourcing Group CRO Summit, taking place December 2–3, 2025. This event will explore how CRO partnerships are redefining operational excellence, innovation, and flexibility across today’s evolving development landscape.